Widely used:Recently Viewed
Clear All
$1.97
$-0.01
(-0.51%)
As on 17-Apr-2025 16:00EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$5 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
0
ROE
-0.66 %
ROCE
--
Div. Yield
0 %
Book Value
3.63
EPS
--
CFO
$-22.11 Mln
EBITDA
$-23.81 Mln
Net Profit
$-65.47 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Creative Medical Technology Holdings (CELZ)
| -14.72 | -39.76 | -9.63 | -62.12 | -57.79 | -30.33 | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Creative Medical Technology Holdings (CELZ)
| -49.61 | 20.97 | -84.10 | -38.22 | -96.97 | -26.54 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.23 | 44.87 | -- | -- | |
| 3.67 | 1.88 | -- | -281.09 | |
| 0.24 | 6.28 | -- | -1185.51 | |
| 0.60 | 3.49 | -- | -- |
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers... CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. Address: 211 East Osborn Road, Phoenix, AZ, United States, 85012 Read more
Co-Founder, Chairman, President & CEO
Mr. Timothy Warbington
Co-Founder, Chairman, President & CEO
Mr. Timothy Warbington
Headquarters
Phoenix, AZ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Creative Medical Technology Holdings Inc (CELZ) stood at $ 13 Mln as on 31-Mar-25
The share price of Creative Medical Technology Holdings Inc (CELZ) is $1.97 (NASDAQ) as of 17-Apr-2025 16:00 EDT. Creative Medical Technology Holdings Inc (CELZ) has given a return of -57.79% in the last 3 years.
Creative Medical Technology Holdings Inc (CELZ) has a market capitalisation of $ 5 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Creative Medical Technology Holdings Inc (CELZ) is 0.79 times as on 17-Apr-2025, a 65% discount to its peers’ median range of 2.26 times.
Since, TTM earnings of Creative Medical Technology Holdings Inc (CELZ) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Creative Medical Technology Holdings Inc (CELZ) and enter the required number of quantities and click on buy to purchase the shares of Creative Medical Technology Holdings Inc (CELZ).
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, which is in IND-enabling phase, to treat infertility as a result of premature ovarian failure; iPSCelz, which is in pre-clinical stage, a platform to make cell type in the body; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. Address: 211 East Osborn Road, Phoenix, AZ, United States, 85012
The CEO & director of Mr. Timothy Warbington. is Creative Medical Technology Holdings Inc (CELZ), and CFO & Sr. VP is Mr. Timothy Warbington.
There is no promoter pledging in Creative Medical Technology Holdings Inc (CELZ).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
4
|
|
|
1
|
|
|
0
|
|
|
0
|
| Creative Medical Technology Holdings Inc. (CELZ) | Ratios |
|---|---|
|
Return on equity(%)
|
-97.78
|
|
Operating margin(%)
|
-46474.63
|
|
Net Margin(%)
|
-45042.94
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Creative Medical Technology Holdings Inc (CELZ) was $0 Mln.
